News headlines about Integra Lifesciences (NASDAQ:IART) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Integra Lifesciences earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the life sciences company an impact score of 46.3150634753743 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
IART has been the topic of a number of recent analyst reports. TheStreet upgraded Integra Lifesciences from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. BidaskClub upgraded Integra Lifesciences from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research report on Thursday, January 11th. Barclays restated a “hold” rating and issued a $53.00 price target on shares of Integra Lifesciences in a research report on Tuesday, January 9th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $52.00 price target on shares of Integra Lifesciences in a research report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $52.70.
Integra Lifesciences (IART) opened at $52.26 on Friday. Integra Lifesciences has a 12-month low of $40.51 and a 12-month high of $56.42. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. The stock has a market capitalization of $4,036.09, a PE ratio of 85.67, a price-to-earnings-growth ratio of 1.64 and a beta of 0.67.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.